| 磷酸芦可替尼依托泊苷联合DDGP方案在NK/T细胞淋巴瘤相关噬血细胞综合征初始诱导治疗的疗效及安全性研究 |
| |
| 引用本文： | 王宇,耿祖瑞,张蕾,柳喜洋,张明智,常宇. 磷酸芦可替尼依托泊苷联合DDGP方案在NK/T细胞淋巴瘤相关噬血细胞综合征初始诱导治疗的疗效及安全性研究[J]. 中国肿瘤临床, 2023, 50(4): 190-195. DOI: 10.12354/j.issn.1000-8179.2023.20221557 |
| |
| 作者姓名： | 王宇 耿祖瑞 张蕾 柳喜洋 张明智 常宇 |
| |
| 作者单位： | 郑州大学第一附属医院肿瘤科，河南省淋巴瘤诊疗中心（郑州市450052） |
| |
| 基金项目： | 本文课题受国家自然科学基金青年项目（编号:82000204）资助 |
| |
| 摘 要： | 目的：探讨以磷酸芦可替尼、依托泊苷联合DDGP(RuE-DDGP)方案初始诱导治疗NK/T细胞淋巴瘤相关噬血细胞综合征（NK/T-cell lymphoma-associated hemophagocytic syndrome,NK/T-LAHS）的临床疗效及安全性。方法：分析郑州大学第一附属医院2021年1月至2022年6月收治的11例采用RuE-DDGP方案治疗的NK/T-LAHS患者的临床资料，对其疗效、不良反应及预后进行回顾性分析。结果：11例患者中9例为男性，2例为女性，中位年龄为30(20～75)岁。治疗2周后11例均获部分缓解（partial remission,PR），治疗4周后10例评效为PR,1例因死亡未评效。治疗2周后总体缓解率（overall remission rate,ORR）为100%，治疗4周后ORR为90.9%。中位总生存期（median overall survival,mOS）为3.0(0.7～15.5)个月，中位无进展生存期（median progression-free survival,mPFS）为3.0(0.7～15.5)个月。在随访期间未...
|
| 关 键 词： | NK/T细胞淋巴瘤 噬血细胞综合征 磷酸芦可替尼 安全性 疗效 |
| 收稿时间： | 2022-11-04 |
Efficacy and safety of ruxolitinib phosphate and etoposide combined with DDGP as an initial induction regimen for patients with NK/T-cell lymphoma-associated hemophagocytic syndrome |
| |
| Affiliation: | Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Lymphoma Diagnosis and Treatment Center, Zhengzhou 450052, China |
| |
| Abstract: | Objective: To investigate the clinical efficacy and safety of ruxolitinib phosphate and etoposide combined with cisplatin, dexamethasone, gemcitabine, and pegaspargase (RuE-DDGP) as an initial induction regimen for the treatment of natural killer/T-cell lymphoma-associated hemophagocytic syndrome (NK/T-LAHS). Methods: The clinical data for 11 patients with NK/T-LAHS treated with the RuE-DDGP regimen in The First Affiliated Hospital of Zhengzhou University from January 2021 to June 2022 were retrospectively analyzed for treatment efficacy, adverse effects, and prognosis. Results: Among the 11 patients, there were nine males and two females, with a median age of 30 (20–75) years. After 2 weeks of treatment, all 11 patients achieved partial remission (PR), with an overall remission rate (ORR) of 100%. After 4 weeks of treatment, 10 patients achieved PR and one was not evaluated due to death. The median overall survival （mOS) time was 3 (0.7–15.5) months, and the median progression-free survival (mPFS) time was 3 (0.7–15.5) months. No treatment-related serious adverse events were observed during the follow-up period. Conclusions: The RuE-DDGP treatment regimen is safe and effective for patients with NK/T-LAHS during initial induction therapy. |
| |
| Keywords: | |
|
| 点击此处可从《中国肿瘤临床》浏览原始摘要信息 |
|
点击此处可从《中国肿瘤临床》下载免费的PDF全文 |
|
